News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
ReNeuron Says Initial Tests On Stroke Treatment OK
November 18, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Stem-cell firm ReNeuron Group Plc (RENE.L: Quote, Profile, Research) said on Friday that initial tests on its stroke treatment ReNOO1 found it did not form tumours, a factor it says is key for approval to carry out human trials.
Twitter
LinkedIn
Facebook
Email
Print
Preclinical
Europe
MORE ON THIS TOPIC
Rare diseases
FDA Signs Off on Neurogene’s ‘Best-Case Scenario’ Pivotal Study Design for Rett Syndrome
July 1, 2025
·
2 min read
·
Tristan Manalac
Obesity
Protagonist Enters Obesity Fray With Triple-G Pill, Eyeing 2026 Clinical Start
July 1, 2025
·
2 min read
·
Tristan Manalac
Lymphoma
Pfizer Ends Mid-Stage Trial for CD47 Blood Cancer Drug, Citing Recruitment Problems
July 1, 2025
·
2 min read
·
Tristan Manalac
Cancer
Amgen’s Antibody Improves Overall Survival in Phase III Gastric Cancer Test
June 30, 2025
·
2 min read
·
Dan Samorodnitsky
